Reuters exclusively reported that U.S. life sciences company Illumina is in talks with European Union (EU) antitrust regulators to divest Grail ahead of an expected EU veto of its $7.1 billion acquisition of the biotechnology company. The European Commission confirmed the Reuters story the next day and blocked the deal because remedies offered by Illumina did not fully address the EU competition enforcer’s concerns.

The post Reuters reveals Illumina in talks with EU regulators to divest Grail appeared first on Reuters News Agency.